Automate Your Wheel Strategy on ILMN
With Tiblio's Option Bot, you can configure your own wheel strategy including ILMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ILMN
- Rev/Share 27.2767
- Book/Share 14.8931
- PB 5.659
- Debt/Equity 1.1009
- CurrentRatio 1.8562
- ROIC 0.3203
- MktCap 13341524000.0
- FreeCF/Share 5.4654
- PFCF 15.3527
- PE -13.8865
- Debt/Assets 0.4217
- DivYield 0
- ROE -0.4649
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | ILMN | Citigroup | -- | Neutral | $130 | $90 | March 4, 2025 |
| Downgrade | ILMN | HSBC Securities | Buy | Hold | -- | $100 | Feb. 28, 2025 |
| Downgrade | ILMN | Barclays | Equal Weight | Underweight | $130 | $100 | Feb. 10, 2025 |
| Downgrade | ILMN | TD Cowen | Buy | Hold | $177 | $140 | Feb. 7, 2025 |
| Downgrade | ILMN | Citigroup | Buy | Neutral | $190 | $165 | Dec. 11, 2024 |
| Upgrade | ILMN | HSBC Securities | Hold | Buy | -- | $180 | Oct. 17, 2024 |
| Upgrade | ILMN | Argus | Hold | Buy | -- | -- | Aug. 28, 2024 |
| Upgrade | ILMN | Daiwa Securities | Neutral | Buy | $120 | $154 | Aug. 16, 2024 |
News
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases.
Read More
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Read More
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
Published: May 28, 2025 by: PRNewsWire
Sentiment: Neutral
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System SAN DIEGO , May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more …
Read More
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Read More
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate modified.
Read More
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Published: May 13, 2025 by: PRNewsWire
Sentiment: Neutral
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.
Read More
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Published: May 13, 2025 by: PRNewsWire
Sentiment: Neutral
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.
Read More
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
Read More
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Dave Westenberg - Piper Sandler Jack Meehan - Nephron Vijay Kumar - Evercore Tycho Peterson - Jefferies Conor McNamara - RBC Capital Markets Mike Ryskin - Bank of America Kyle Mikson - Canaccord Operator Good day ladies and gentlemen, and welcome to the First Quarter 2025 Illumina Earnings Conference Call. At this time, all participants are …
Read More
Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Read More
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO , May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery …
Read More
Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios
Published: April 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.
Read More
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Published: April 15, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
Read More
Here's Why Illumina (ILMN) is a Strong Value Stock
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Positive
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years.
Read More
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
Read More
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Published: March 19, 2025 by: PRNewsWire
Sentiment: Neutral
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO , March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic …
Read More
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Read More
Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year
Published: March 06, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina leads as highest-scoring U.S. company in its industry SAN DIEGO , March 6, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices), and recognized for the fourth year in a row as a Sustainability Yearbook Member. Illumina, which scored in the top 15% of the Best-in-Class World Index, also ranked as the highest-scoring US company in the Life Sciences …
Read More
Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience …
Read More
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.
Read More
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Read More
Here's Why Illumina (ILMN) is a Strong Growth Stock
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
ILMN vs. ALNY: Which Stock Is the Better Value Option?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Illumina Stock Got Mashed on Monday
Published: February 10, 2025 by: The Motley Fool
Sentiment: Negative
On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.
Read More
About Illumina, Inc. (ILMN)
- IPO Date 2000-07-28
- Website https://www.illumina.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Jacob Thaysen Ph.D.
- Employees 8970